Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eli Lilly and Co announces detailed results from two phase III studies testing both doses of Dulaglutide vs. Insulin Glargine


Monday, 16 Jun 2014 06:15pm EDT 

Eli Lilly and Co:Releases detailed results from two trials that showed treatment with once-weekly dulaglutide 1.5 mg resulted in superior reductions in HbA1c from baseline compared to insulin glargine, with lower risk for hypoglycemia.1,2Dulaglutide is investigational glucagon-like peptide-1 (GLP-1) receptor agonist being studied for the treatment of type 2 diabetes. 

Company Quote

86.14
1.29 +1.52%
2 Jul 2015